* Sangamo Therapeutics Inc reported quarterly adjusted earnings of 4 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -59 cents. The mean expectation of eight analysts for the quarter was for a loss of 3 cents per share. Wall Street expected results to range from -14 cents to 16 cents per share.
* Revenue rose 425.8% to $49.41 million from a year ago; analysts expected $17.94 million.
* Sangamo Therapeutics Inc's reported EPS for the quarter was 4 cents.
* The company reported quarterly net income of $9.39 million.
* Sangamo Therapeutics Inc shares had risen by 211.7% this quarter and gained 397.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 22.1% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Sangamo Therapeutics Inc is $3.00 This summary was machine generated from LSEG data November 12 at 11:16 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.03 0.04 Beat
Jun. 30 2024 -0.15 -0.18 Missed
Mar. 31 2024 -0.21 -0.27 Missed
Dec. 31 2023 -0.26 -0.34 Missed
Comments